- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Sinclair Pharma signs distribution agreement with Graceway
World report - Sinclair Pharma, based in the U.K., has signed an agreement to sell U.S. distribution rights for Atopiclair cream and lotion, for the treatment of atopic dermatitis, to U.S.-based Graceway.
World report
- Sinclair Pharma, based in the U.K., has signed an agreement to sell U.S. distribution rights for Atopiclair cream and lotion, for the treatment of atopic dermatitis, to U.S.-based Graceway, according to Pharmaceutical Business Review.
Sinclair received 3.1 million in cash rather than future royalties. Though, the payment is equivalent to the royalties Sinclair would have received from Graceway over the next five years. Graceway also relinquished its right of first refusal for Sinclair’s dermatology products for the U.S.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
